Drug Development Pipeline
ABBV-2222 (formerly GLPG2222)
Restore CFTR Function
ABBV-2222 (formerly GLPG2222) is a new CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A phase 2a study to test the safety and tolerability of ABBV-2222 in people with CF who have two copies of the F508del CFTR mutation is ongoing.
This program is sponsored by Abbvie and is being conducted within the Therapeutics Development Network.
Recent ABBV-2222 (formerly GLPG2222) Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More